1

Monitoring Body Composition Change for Intervention Studies with Advancing 3D Optical Imaging Technology in Comparison to Dual-Energy X-Ray Absorptiometry

Michael C. Wong^{1,2}, Jonathan P. Bennett^{1,2}, Lambert T. Leong¹, Isaac Y. Tian³, Yong E. Liu¹, Nisa N. Kelly¹, Cassidy McCarthy⁴, Julia MW Wong⁵, Cara B. Ebbeling⁵, David S. Ludwig⁵, Brian A. Irving⁶, Matthew C. Scott^{4,6}, James Stampley⁶, Brett Davis⁶, Neil Johannsen^{4,6}, Rachel Matthews⁶, Cullen Vincellette⁶, Andrea K. Garber⁷, Gertraud Maskarinec¹, Ethan Weiss⁷, Jennifer Rood⁴, Alyssa N. Varanoske^{8, 9}, Stefan M. Pasiakos⁸, Steven B. Heymsfield⁴, John A. Shepherd^{1,2}

¹ Department of Epidemiology, University of Hawaii Cancer Center, Honolulu, HI;

² Department of Human Nutrition, Food and Animal Sciences, University of Hawaii at Manoa, Honolulu, HI;

³ Paul G. Allen School of Computer Science and Engineering, University of Washington, Seattle, WA;

⁴ Pennington Biomedical Research Center, Baton Rouge, LA;

⁵ New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, MA;

⁶ Louisiana State University, School of Kinesiology, Baton Rouge, LA;

⁷ Department of Pediatrics, University of California San Francisco, San Francisco, CA;

⁸ Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA;

⁹ Oak Ridge Institute for Science and Education, Oak Ridge, TN

Funding

Phases of this study were funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH R01 DK R01DK109008), National Institute of Aging (R21AG058181), the US Army Medical Research and Development Command, Military Operational Medicine Research Program Grant W81XWH-19-C-0162. Supported in part by an appointment to the U.S. Army Research Institute of Environmental Medicine administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Army Medical Research and Development Command.

Clinical Trials Number

Shape Up! Adults (NCT03637855, https://clinicaltrials.gov/ct2/show/NCT03637855)

Macronutrients and Body Fat Accumulation: A Mechanistic Feeding Study (NCT03394664, https://clinicaltrials.gov/ct2/show/NCT03394664)

2

Resistance Exercise and Low-Intensity Physical Activity Breaks in Sedentary Time to ImproveMuscleandCardiometabolicHealth(NCT03771417,https://clinicaltrials.gov/ct2/show/NCT03771417)

TimeRestrictedEatingonWeightLoss(NCT03393195,https://clinicaltrials.gov/ct2/show/NCT03393195)

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations (NCT04120363, <u>https://clinicaltrials.gov/ct2/show/NCT04120363</u>)

Conflicts of Interest

SBH reports his role on the Medical Advisory Boards of Tanita Corporation, Amgen, and Medifast; he is also an Amazon Scholar.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations.

All other authors have no disclosures.

Corresponding Author

John A. Shepherd

701 Ilalo Street

Honolulu Hawaii 96813

Email: johnshep@hawaii.edu

Running Title: Monitoring Body Composition with 3D Optical Shape

Abbreviations: 3DO (three-dimensional optical), ALM (appendicular lean mass), ALMI (appendicular lean mass index), CV (coefficient of variation), DXA (dual-energy X-ray absorptiometry), FM (fat mass), FFM (fat-free mass), LSC (least significant change), PCA (principal component analysis), PCs (principal components), VAT (visceral adipose tissue)

3

1 ABSTRACT

2 Background

3 Recent three-dimensional optical (3DO) imaging advancements have provided more accessible,

- 4 affordable, and self-operating opportunities for assessing body composition. 3DO is accurate
- 5 and precise with respect to clinical measures made by dual-energy X-ray absorptiometry (DXA).
- 6 However, the sensitivity for monitoring body composition change over time with 3DO body
- 7 shape is unknown.

8 **Objective**

9 To evaluate 3DO's ability to monitor body composition changes across multiple intervention 10 studies.

11 Methods

12 A retrospective analysis was performed using intervention studies on healthy adults that were 13 complimentary to the cross-sectional study, Shape Up! Adults. Each participant received a DXA (Hologic Discovery/A system) and 3DO (Fit3D ProScanner) scan at baseline and follow-up. 3DO 14 meshes were digitally registered and reposed using Meshcapade to standardize the vertices 15 and pose. Using an established statistical shape model, each 3DO mesh was transformed into 16 17 principal components (PCs), which were used to predict whole-body and regional body 18 composition values using published equations. Body composition changes (follow-up minus baseline) were compared to DXA with linear regression. 19

20 Results

4

The analysis included 133 participants (45 females) in six studies. The mean (SD) length of follow-up was 13 (5) weeks, range 3-23 weeks. Agreement between 3DO and DXA (R²) for changes in total fat mass (FM), total fat-free mass (FFM), and appendicular lean mass, respectively, were 0.86, 0.73, and 0.70 with RMSEs of 1.98 kg, 1.58 kg, and 0.37 kg in females, and 0.75, 0.75, and 0.52 with RMSEs of 2.31 kg, 1.77 kg, and 0.52 kg in males. Further adjustment with demographic descriptors improved the 3DO change agreement to changes observed with DXA.

28 Conclusions

As compared to DXA, 3DO was highly sensitive in detecting body shape changes over time. The 3DO method was sensitive enough to detect even small changes in body composition during 31 intervention studies. The safety and accessibility of 3DO allows users to self-monitor on a 32 frequent basis throughout interventions.

Keywords: Body Composition, Three-dimensional Optical Imaging, DXA, Interventions, Weight loss, Monitoring

5

35 **INTRODUCTION**

Obesity remains an area of concern as global prevalence continues to rise (1-3). 36 37 According to the Center for Disease Control and Prevention (CDC), more than 42% of adults in 38 the United States were considered obese in 2018, while the prevalence was approximately 30% 39 two decades prior (4). To counter the obesity epidemic, diet and physical activity interventions have been studied extensively to target weight loss (5, 6). However, metanalyses have shown 40 that weight is only loosely associated with metabolic health (7) and initial changes in response 41 42 to intervention are small and quickly undone long-term (6, 8). On the other hand, a range of changes in body composition (reduced total body, abdominal and visceral fat, and increased 43 44 muscle mass) can be produced through diet or exercise intervention and are consistently 45 associated with decreased cardiovascular disease risk (9, 10). Further, decrements in skeletal muscle, particularly in the elderly, can lead to losses in strength and endurance, reductions in 46 47 energy expenditure, and an increased risk of insulin resistance (11). Nevertheless, measures of body composition have been relegated to research and specialized facilities while clinical care 48 continues to rely on weight as a flawed marker of health. 49

Another pressing reason to limit our reliance on weight is the differing relative weight of the compartments and tissues. Garrow (12) suggested, and Prentice et al. (13) concurred, that weight loss is typically 25% fat-free mass (FFM, i.e. lean soft tissue + bone mineral content) and 75% fat loss. However, recent research suggested this "25/75 rule of thumb" may not accurately describe various weight loss interventions. The amount FFM lost depends on energy intake, diet composition, sex, baseline adiposity, inactivity or type and physical activity level, and potentially metabolic and hormonal responses (14, 15). As such, it may not be appropriate

medRxiv preprint doi: https://doi.org/10.1101/2022.11.14.22281814; this version posted January 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

6

57 to only monitor weight in interventions as FFM might be lost at a greater proportion. By 58 monitoring body composition, investigators receive a more accurate assessment of their 59 intervention's efficacy.

Body composition by dual-energy X-ray absorptiometry (DXA) has been used extensively in clinical settings for its accuracy and precision of whole-body and regional measurements (16). Although DXA provides clinically useful measurements (e.g., bone mineral density, VAT, fat, and lean mass), it requires expensive radiological equipment, qualified technicians, and may not be feasible or accessible for routine clinical practice or frequent monitoring. The ideal body composition method should be affordable, accessible, free of ionizing radiation, and not require radiological-qualified technicians.

Three-dimensional optical (3DO) imaging has become increasingly accessible, made 67 large advancements in recent years, and is safe to use repeatedly (17, 18). 3DO scanners 68 69 provide accurate and precise digital anthropometry in comparison to criterion methods and 70 output a 3D mesh that represents a person's entire shape (19, 20). 3DO shape has shown to be 71 highly predictive of DXA body composition (21-24). The next pressing issue is whether 3DO could successfully capture changes in body composition as different modalities have not 72 73 validated well longitudinally to standard methods (25). However, the lack of available longitudinal data has limited the assessment of 3DO in monitoring body composition changes. 74 75 The hypothesis of the study was that 3DO can monitor change with a similar sensitivity to DXA 76 given previous cross-sectional accuracy and precision. Therefore, the objective of this study was 77 to evaluate 3DO's accuracy for monitoring body composition changes across a variety of 78 intervention studies in comparison to DXA.

7

79 METHODS

80 Study Design

81 The current study was a retrospective analysis of six complimentary intervention studies to the Shape Up! Adults study (NIH RO1 DK109008, ClinicalTrials.gov ID NCT03637855), which 82 was originally a cross-sectional study with a planned longitudinal arm. In order to study 3DO's 83 ability to monitor body composition over time, collaborators adopted our DXA and 3DO 84 85 protocol. The studies included Time-restricted Eating on Weight Loss (TREAT) (26); Macronutrients and Body Fat Accumulation: A Mechanistic Feeding Study (FB4: Framingham, 86 87 Boston, Bloomington, Birmingham, and Baylor) (27-29); Resistance Exercise and Low-Intensity Physical Activity Breaks in Sedentary Time to Improve Muscle and Cardiometabolic Health Pilot 88 Study (REALPA, NIH R21AG058181, ClinicalTrials.gov ID NCT03771417) (30), Louisiana State 89 90 University (LSU) Athletes; Trial of Testosterone Undecanoate for Optimizing Performance 91 During Military Operations (OPS II) (31, 32); and patients with bariatric surgery. If available, study-specific information (e.g., site, protocol, aims) can be found on ClinicalTrials.gov (Table 92 **1**). All study protocols were previously approved by their respective Institutional Review Board. 93

The TREAT participants were only allowed to consume food between 12 pm and 8 pm with the goal of fat loss (26). The FB4 cohort was given a hypocaloric, low-carbohydrate diet with the goal to lose 15±3% of baseline body weight (27-29). The REALPA study introduced whole-body resistance exercise (2 days/week) alone (i), or with moderate intensity aerobic exercise (50 min/day, 3 days/week at 4 METS) (ii), or low-intensity physical activity (LPA) breaks in sedentary time (~10 min/break, 6 breaks/day, 5 days/week at 2METS) in adults 65-80 years

8

of age to observe changes to muscle and cardiometabolic health markers after the 16-week 100 101 long intervention. A subset of the REALPA participants who had both 3DO and DXA scans available for analysis were included in this retrospective study. (30). The LSU athletes were 102 103 female basketball players that were measured at the beginning and through training camp 104 (ranging 1-5 months), evaluating body composition as a result of a preseason training program. The OPS II study tested the effects of an intramuscular injection of testosterone undecanoate 105 106 compared to placebo on changes in muscle and fat mass in recreationally-active young males 107 undergoing simulated military operational stress consisting of sleep restriction, high exerciseinduced energy expenditure, and limited energy intake (31, 32). The bariatric patients who 108 109 were recruited from the University of California, San Francisco (UCSF) received bariatric surgery (surgery type was not recorded) with the goal of weight-loss. Although weight loss or body 110 111 composition changes was not the goals of each study, the current aim of this analysis was to 112 evaluate 3DO's ability to monitor body composition changes in comparison to DXA.

113 **Participants**

All participants provided informed consent before participation. Participants were 114 deemed ineligible for this analysis if they were pregnant, breast feeding, had missing limbs, 115 non-removable metal (e.g., joint replacements), previous body-altering surgery (e.g., breast 116 augmentation), unable to stand still for one minute, or lie still for 3 minutes. Participants 117 118 received same-day whole-body 3DO and DXA scans at baseline and follow-up. If the study had 119 two follow-up appointments, the first of the two was used and will be considered as the 120 "follow-up" in the current analysis. Participants were excluded from the analysis if they were 121 missing either baseline or follow-up data from either DXA or 3DO.

9

122 **DXA**

123 Height and weight were measured prior to the DXA scan. Participants received a single 124 whole-body DXA scan with a Hologic Discovery/A system (Hologic Inc., Marlborough, 125 Massachusetts) according to International Society for Clinical Densitometry guidelines (33). 126 Participants laid supine on the scanning bed and were positioned by the DXA technician with arms by the side and feet internally rotated. Scans took approximately three minutes for the 127 whole-body scan. All raw scans from each study were securely transferred to the University of 128 129 Hawaii Cancer Center and analyzed by a single certified technologist using Hologic Apex version 130 5.6 with the National Health and Nutrition Examination Survey Body Composition Analysis 131 calibration option disabled (34). After analysis, proprietary algorithms automatically generate 132 body composition values. DXA measurements used in this analysis included whole-body and regional (i.e., arms, legs, trunk) fat and fat-free measures. 133

134 **Three-Dimensional Optical**

135 Participants changed into form-fitting tights, a swim cap, and a sports bra if female. 136 Female participants from the FB4 used form-fitting swimsuits. 3DO surface scans were taken on the Fit3D ProScanner version 4.x (Fit3D Inc., San Mateo, California). Participants grasped 137 telescoping handles on the scanner platform and stood upright with shoulders relaxed and 138 arms positioned straight and abducted from their torso. The platform rotates once around and 139 140 takes approximately 45 seconds for the completion of the scan. Final point clouds were 141 converted to a mesh connected by triangles with approximately 300,000 vertices and 600,000 142 faces representing the body shape (22).

10

Fit3D meshes were sent to Meshcapade (Meshcapade GmbH, Tubingen, Germany) for 143 144 registration and to be digitally reposed. Their algorithm registers each mesh to a 110,000-vertex template with complete anatomical correspondence. Each vertex corresponds to a specific 145 anatomical location across all registered meshes. All meshes were digitally reposed to a T-pose, 146 147 where the person was standing straight, arms were brought horizontal and in the plane with the body, and arms and legs were straightened (35). The registered meshes were transformed 148 into principal component (PC) space from an established statistical shape model (24). Principal 149 150 component analysis orthogonalizes and reduces the dimensionality of the data so that fewer 151 variables are needed to describe the data's variance (21). Total FM and regional (i.e., arms, legs, 152 trunk, VAT) body composition estimates were derived previously using either exclusively PC descriptors of shape or PC descriptors with demographic adjustments (24). In this study, PC 153 154 only body composition equations were used since complete demographics and 155 anthropometrics were not available on all cohorts. Total FFM and percent fat (%fat) were derived dependently from total FM and total body mass. Appendicular lean mass (ALM) was 156 157 defined as the sum of lean soft tissue masses for legs and arms by convention (36). ALM index (ALMI) was derived by dividing ALM by height-squared. 158

Average 3DO body shape representations were created to visualize the average shape at baseline and follow-up for each intervention study. PCs were averaged by study intervention to make an average vector of PCs, which was then inverted back into coordinate space (x, y, and z) to acquire the image.

163 **Statistical Analysis**

11

Body composition change for all variables was defined as follow-up minus baseline. 3DO 164 165 body composition change was compared to DXA body composition change using linear regression. Bland-Altman plots were made for the cross-sectional comparisons. Coefficient of 166 determination (R²), Lin's concordance coefficient (CCC), and root mean square error (RMSE) 167 were used to report the relationship and accuracy of the comparison. Scatter plots were used 168 to visualize the comparison. Additional adjustments were made to explain any potential bias 169 170 using stepwise forward linear regression and five-fold cross-validation. Potential covariates included ethnicity and baseline height, weight, BMI, and age as well as changes in weight, 171 height, and BMI. Covariates remained in the model if they had a p-value <0.05. The least 172 173 significant change (LSC) was used to determine if the change in the body composition measure was significantly different (95% confidence) than zero (37). Student's t-test was used to 174 175 evaluate mean differences between 3DO and DXA outputs. P-value < 0.05 was considered 176 statistically significant.

The LSCs used in this analysis were derived from Wong et al. (24). LSC is defined as 2.77 177 x precision error (21, 37). Female LSC for FM, FFM, and %fat was 1.52 kg, 1.52 kg, and 2.27% for 178 179 3DO, while 0.64 kg, 0.75 kg, and 0.91% for DXA, respectively. Male LSC for FM, FFM, and %fat was 1.22 kg, 1.22 kg, and 1.58% for 3DO, while 0.69 kg, 0.94 kg, and 0.78% for DXA, 180 respectively. Since ALM was not reported in the previous publication, in order to get the 181 182 precision error to calculate the LSC, the test-retest precision for ALM was derived using the same sample from Wong et al. (24). Lastly, Cohen's kappa analysis was utilized to assess the 183 consistency between the DXA and 3DO report for each level, considering any agreement that 184 may have happened due to chance. The kappa scores can be interpreted as follows: 0-0.20 = no 185

12

186	agreement, 0.21-0.39 = fair agreement, 0.40-0.59 = moderate agreement, 0.60-0.79 =
187	substantial agreement, 0.80-0.99 = near perfect agreement, and 1 = perfect agreement (38).
188	To test Garrow's (12) and Prentice et al.'s (13) suggestion that 25% of weight loss is
189	FFM, change in total FFM was divided by the absolute change in weight multiplied by 100
190	([Δ FFM /absolute Δ weight]*100). This was applied to those who had a negative weight change
191	(weight loss). The absolute change in weight was used in order to evaluate gains or losses in
192	FFM.

Experimental models were created using the change in PCs (Δ PCs) to test if different modeling methods would improve the body composition change predictions. Model 1 used the Δ PCs, model 2 used the Δ PCs and baseline total fat mass, model 3 used the Δ PCs and baseline PCs, model 4 used the baseline and follow-up PCs, and model 5 used the Δ PCs and change in weight. These models were built with stepwise forward linear regression with five-fold crossvalidation. All statistical analyses were done in R version 4.2.1 (R Core Teams, Vienna, Austria).

13

199 **RESULTS**

200 One hundred and thirty-three participants (43 female and 85 male) were included in the 201 final analysis (Table 2). One-hundred sixty-four participants were excluded for dropout (n=4), 202 unavailable 3DO or DXA data at one or both timepoints (n=157), movement artifacts (n=2), or 203 mislabeled data (n=1) (Supplemental Figure 1). The time between baseline and follow-up DXA scans across all studies ranged from three to twenty-three weeks (Figure 1). Females and males 204 205 lost on average 3.5 kg and 5.4 kg of total FM, 1.8 kg and 3.4 kg of total FFM, and 30 g and 100 g 206 of VAT as a result of interventions, respectively, according to DXA. The majority of the body composition changes occurred in the trunk for both sexes. Average body shapes were 207 208 presented at baseline and follow-up for each study intervention (Figure 2).

In females (Figure 3), 3DO and DXA total FM and FFM at baseline (R²s; 0.91 and 0.84; 209 RMSE; 3.3 kg and 3.3 kg, respectively) and follow-up (R²s; 0.89 and 0.84; RMSE; 2.8 kg and 2.8 210 211 kg, respectively) were highly correlated, while %fat and ALM were moderately correlated (R²s: 212 0.61 – 0.79). Female Bland-Altman plots are shown in **Supplemental Figure 2**. Slight 213 proportional bias was observed in the baseline total FM from a single outlier with high leverage but not seen in the follow-up. In the comparison of 3DO body composition changes to DXA 214 (Supplemental Table 1), 3DO achieved an R² of 0.86, 0.73, 0.23; and 0.70, CCC of 0.90, 0.82, 215 0.47, and 0.81; RMSE of 1.98 kg, 1.58 kg, 2.2%, 0.37 kg for total FM, total FFM, %fat, and ALM, 216 217 respectively. Mean differences were observed for VAT, ALM, ALMI, and leg FFM (30 g, 0.19 kg, 0.07 kg/m^2 , 0.16 kg, respectively, p-value < 0.05). After adjustments for possible covariates in 218 219 the stepwise linear regression models with forward selection (Supplemental Table 2), weight change further explained variance in total FM, FFM, and ALM, while changes in BMI further 220

14

explained variance in %fat change, which modestly improved the R²s to 0.90, 0.80, 0.51, and 221 222 0.79, respectively. The adjustments with demographic covariates alleviated residual bias between 3DO and DXA change. Mean differences (i.e., VAT, ALM, ALMI, and leg FFM) were no 223 224 longer observed after adjustments (p-value = 0.99). The green glyphs (Figure 3 and 4) symbolizes the participants that exceeded both the DXA and 3DO LSCs, the purple glyphs were 225 226 those who did not exceed DXA nor 3DO's LSC, and the orange and blue glyphs exceeded one 227 LSC but not the other. The LSCs were depicted with the orange vertical lines (3DO) or the blue 228 horizontal lines (DXA).

In males (Figure 4), 3DO and DXA total FM and FFM at baseline (R²s; 0.88 and 0.84; 229 RMSE; 3.7 kg and 3.6 kg, respectively) and follow-up (R²s; 0.88 and 0.85; RMSE; 3.3 kg and 3.2 230 kg, respectively) were highly correlated, while % fat and ALM were moderately correlated (R^2 s: 231 0.60 – 0.75). Male Bland-Altman plots are shown in **Supplemental Figure 3**. Proportional bias 232 233 was observed in total FM and %fat due to a single outlier with high leverage. Not bias was observed in total FFM and ALM. In the comparison of 3DO body composition changes to DXA 234 (Supplemental Table 1), 3DO achieved an R² of 0.75, 0.75, 0.25, and 0.52; CCC of 0.76, 0.78, 235 236 0.39, and 0.64; and RMSE of 2.3 kg, 1.8 kg, 2.4%, and 0.5 kg for total FM, total FFM, %fat, and ALM, respectively. Of the observed variables in Figure 4, mean differences were observed for 237 total FM, total FFM, %fat, and ALM (p-value<0.001). After adjustments for possible covariates in 238 239 stepwise linear regression with forward selection (**Supplemental Table 2**), R²s modestly improved for changes in total FM, FFM, %fat, and ALM to 0.80, 0.76, 0.42, and 0.56, 240 241 respectively. Mean differences in total FM, total FFM, %fat, and ALM were no longer observed after adjustments (p-value = 0.99). 242

15

243	3DO predicted regional body composition changes (i.e., arms, legs, and trunk) with R^2 s
244	that ranged from $0.39 - 0.91$ and RMSEs that ranged from $0.16 - 1.3$ kg in females and males
245	(Supplemental Table 1). 3DO and DXA found significant changes in the majority of the sample
246	for total FM (69%), total FFM (78%), %fat (53%), and ALM (78%) (Supplemental Table 3).
247	Cohen's kappa showed that 3DO had a moderate agreement to DXA for most outputs.

From the total sample, 64% of females and 90% of males lost weight after intervention. 248 249 Of those that lost weight, % FFM loss relative to weight loss ranged from -1370% to 478% as 250 measured by DXA. Among those who lost FFM, 80% of females and 81% of males lost more than 25% FFM relative to their weight loss (Figure 5). The % FFM loss relative to weight loss 251 according to study was on average 36% for Bariatric surgery, 37% for FB4, 27% for OPS II, 313% 252 for Athletes, 85% for TREAT, and 59% for REALPA. The very high percentages were for small 253 weight changes and/or large compartment changes with little overall weight change (e.g., Δ 254 255 FFM /absolute(Δ weight) * 100 for an Athlete = (-1.96/0.36) * 100 = -544%).

The experimental models (**Supplemental Tables 4 and 5**) for females (models 1-5) and males (models 1-3 and 5) predicted change better than the unadjusted results presented in **Supplemental Table 1**. Female models 1, 2, and 3 were the same as male models 1, 2, and 3 after the stepwise regression. The prediction of total FM change improved in both females ($R^2 =$ 0.94, RMSE = 1.29 kg) and males ($R^2 = 0.84$, RMSE = 1.79 kg).

261

16

262 **DISCUSSION**

263 These present findings support 3DO as a sensitive tool assessing changes in body 264 composition, compared to DXA. The current study evaluated 3DO's ability to monitor body 265 composition change with body shape via the 3DO mesh. Previously derived shape models and 266 equations were used to estimate body composition values (24), and 3DO change from baseline to follow-up was compared to DXA change. Overall, 3DO change was highly correlated to DXA 267 268 change, and the two methods agreed on the statistical significance of the change in the 269 majority of the study population. Additional adjustments of demographics explained further 270 variance between 3DO and DXA change. The experimental models showed that specific 271 calibration with changes in shape might improve the body composition change prediction. Additional longitudinal data may further validate the experimental models. Nevertheless, the 272 273 cross-sectional 3DO models produced comparable body composition estimates compared to 274 DXA, which supports our hypothesis that using 3DO imaging is a feasible method to monitor body composition changes. 275

276 With respect to the "rule-of-thumb" by Garrow's (12) and Prentice et al. (13) that 25% of weight loss comes from FFM, the proportion of FFM lost by the vast majority of our sample 277 was greater than 25% (Figure 5). Thus, this "rule-of-thumb" underestimated the loss of FFM for 278 most participants. The loss of FFM varied by study intervention due to differences in protocol, 279 280 type of activity, and objectives. This is a critical area of study given that loss of FFM is associated 281 with diminished strength and decrements in physical functioning, exercise endurance and 282 capacity, metabolic rate, and health (11). This further supports the idea that the relative 283 proportion of FM and FFM change is dependent on energy intake, diet composition, sex,

17

284 baseline adiposity, inactivity or type and level of physical activity level, and potentially 285 metabolic and hormonal responses (14). It should also be noted that the experimental group in the OPS II study received testosterone, which has shown to improve muscle protein kinetics 286 during stress and was a contributing factor to the proportion of FFM loss (32). The LSU athletes 287 and OPS II participants were study examples that monitored body composition for 288 performance. 3DO can also provide an accessible and safe method to monitor body 289 290 composition changes since muscle build-up can play a pivotal role in strength, endurance, and speed. Some participants had percent changes in FFM that were greater than 100%. This was 291 likely due to an undesirable recomposition where the person increased FM and lost FFM, which 292 resulted in a minimal weight change (small denominator). Hydration status may have impacted 293 individuals with minimal changes (15). Because DXA does not measure hydration status, DXA 294 295 has assumptions of hydration built-in, while 3DO estimates were regressed to DXA. The current 296 analysis further emphasized the importance of monitoring body composition, in addition to weight, to better understand changes in health status and performance factors. 297

In the current study, the change in 3DO FM was underestimated while FFM was 298 299 overestimated in both females and males. These changes were not statistically significant in females but were significant in males. A potential reason for the male discrepancies could be 300 that the current sample was beyond the adiposity range of the data used to train the original 301 302 3DO body composition models. The maximum percent fat of the training dataset was 38% (24), while the current population's maximum was 47%. The training dataset lacked the shape 303 variance of males with extreme adiposity and underestimated FM and %fat in this study. 304 However, after adjusting for covariates, these discrepancies were no longer statistically 305

18

significant. Using either the 3DO changes models with demographics or retraining the model
 with high adiposity participants could potentially address this issue.

308 Test-retest precision, also known as short-term precision, has an error that can be used 309 to derive the LSC (2.77 x precision error) (37). Metrics with changes that surpass their LSC 310 values were considered to be significantly greater than zero changes, with a 95% confidence. 3DO and DXA precision errors used for this study were taken from the Shape Up Adults group 311 312 (24). To reduce the 3DO precision error, to be closer to that of DXA, and track body composition 313 changes at the same significance, multiple 3DO scans could be taken and averaged at each time 314 point. For total FM, the 3DO precision errors were 0.44 kg and 0.55 kg as well as 0.25 kg and 315 0.23 kg for DXA in males and females, respectively (24). Assuming a normal distribution of the precision errors, the precision of the averaged 3DO measure from multiple scans improves by 316 the square root of the number of scans (e.g., the average of four scans would lower the 317 318 precision error from 0.44 kg and 0.55 kg to 0.22 kg and 0.27 kg) (39). Unlike DXA, taking multiple scans with 3DO is fast and without additional radiation concerns. Dizziness can be a 319 320 potential hazard, which is listed on the manufacturer warnings and our study consent form. However, our participants did not report dizziness even with multiple scans. 321

322 3DO VAT change compared to DXA VAT change had a low correlation, but this is likely to 323 due to the compressed range of VAT change in our sample. In previous literature, DXA VAT has 324 been shown to be highly correlated to gold standard, magnetic resonance imaging (MRI), cross-325 sectionally (R^2 range: 0.81 – 0.86) (40-42). However, DXA VAT often has proportional bias for 326 individuals with high VAT and has not validated well longitudinally compared to MRI (42, 43). 327 Some of the bias may be explained by technique differences as MRI and CT are analyzed by a

19

cross-section of the abdomen, while DXA is estimated from an X-ray's 2D area. Nevertheless, 328 329 given the cross-sectional correlation of DXA VAT to MRI and cardiometabolic markers, DXA VAT can still be considered an accessible tool to characterize health risks that can prompt health 330 initiatives (44, 45). Since 3DO body shape has been shown to be correlated and predictive of 331 DXA VAT and cardiometabolic markers (21), 3DO may be considered an accessible tool that can 332 be used frequently due to its lack of ionizing radiation concerns. However, users should be wary 333 of DXA and 3DO's ability to accurately monitor VAT changes given the limited amount of 334 335 validation in the literature.

The 3DO vs DXA RMSEs for comparing baseline or follow-up scans were higher (worse) than the RMSEs for the change comparisons (**Figures 3 and 4**). This may be due to the individual systematic bias expressed in the comparison of one technique (3DO) to another (DXA) that is subtracted away when looking at changes in the measures, and the fact that the precision error of both techniques was much lower than this individual systemic bias found in inter-technique comparisons of measures (46).

According to the authors' knowledge, one other study has reported 3DO's ability to 342 monitor body composition change. Tinsley et al. (25) compared the changes in proprietary body 343 composition estimates from 3DO scanners (Fit3D ProScanner, Size Stream SS20 (Size Stream 344 LLC, Cary, NC, USA), and Styku S100 (Styku Comp. Los Angeles, CA, USA)) with changes in 4-345 346 compartment (4C) model measures in 21 volunteers. Changes in 3DO FM underperformed 347 (CCC, 0.22 to 0.40 for total FM) compared to the 4C model. CCC for total FM in this study was 348 much higher (CCC; 0.91 and 0.79) for females and males, respectively, showing better 349 agreement with DXA. However, there were major differences between the two studies. This

20

study had a larger sample size (n=128), greater ethnic-racial diversity, larger body composition changes, publicly available equations, and a different body composition modality (DXA instead of the 4C model, given that data for the 4C model was not available). Larger studies are warranted to fully evaluate 3DO's ability to monitor change using the scanners' proprietary body composition outputs.

This study had several strengths including sample size, variety and lengths of interventions, and an ethnically diverse sample. A study with 128 participants is currently one of the larger body composition change studies. Although the majority of the participants were ethnically white, there was still a representation of other ethnic backgrounds. This study included a variety of diet, physical activity, and surgical interventions that ranged from 3 to 23 weeks and included participants with large as well as little to no body composition changes.

This study is not without limitations. Although the sample size was rather large for a longitudinal analysis, a representative test set could not be made to validate the adjusted and experimental linear models. In addition, results from this study may not be generalizable to populations with poor health status or children (< 18 years old). Future work would be required to address gaps in knowledge in different populations such as infants and children, the accuracy of change in specific subgroups (i.e., BMI, ethnicity, and age), and the assessment of more accessible 3DO technology.

368 CONCLUSION

This study indicated that 3DO body composition changes were highly correlated to DXA and show good feasibility to monitor changes over a variety of interventions. As the

- accessibility and popularity of 3DO continues to grow, more people will be able to use this
- technology to monitor their body composition in clinical and nonclinical settings. The findings of
- this study extend the 3DO literature, which has been limited to cross-sectional performance.

374

22

375 Acknowledgements

376	We thank all the participants for graciously giving their time to be part of the studies, our
377	collaborators at each site for their part in the study, Tyler Carter and Greg Moore at Fit3D for
378	providing us the 3DO data, and Naureen Mahmood and Talha Zaman for providing us the
379	application program interface to register and repose our 3DO data. The data underlying this
380	study cannot be made publicly available because the data contains patient identifying
381	information. Data is available from the Shape Up! Studies for researchers who meet the criteria
382	for access to confidential data. For details and to request an application, please contact John
383	Shepherd johnshep@hawaii.edu or visit <u>www.shapeup.shepherdresearchlab.org</u> .

384 Author Contributions

MCW and JAS designed and conducted the research; MCW, LL, JB, IT, YEL, GM, and JAS were part of the data analysis; JMWW, NNK, CBE, BI, MCS, JS, BD, NMJ, RM, CV, DSL, EW, SBH, and JAS were in charge of their respective study recruitment and protocols; MCW and JAS drafted the manuscript and were responsible over the final content. All authors reviewed and approved the final manuscript.

390

23

REFERENCES

391 1. Wong MC, McCarthy C, Fearnbach N, Yang S, Shepherd J, Heymsfield SB. Emergence of the 392 obesity epidemic: six decade visualization with humanoid avatars. The American journal of clinical 393 nutrition. 2022. 394 Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. New 2. 395 England Journal of Medicine. 2017;376(3):254-66. 396 3. Bennett J, Wong MC, McCarthy C, Fearnbach N, Queen K, Shepherd J, et al. Emergence of the 397 adolescent obesity epidemic in the United States: five-decade visualization with humanoid avatars. 398 International Journal of Obesity. 2022:1-4. 399 Hales CD CM, Fryar CD, and Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: 4. 400 United States, 2017-2018 2020. Available from: https://www.cdc.gov/nchs/data/databriefs/db360-401 h.pdf. 402 5. Arem H, Irwin M. A review of web-based weight loss interventions in adults. Obesity reviews: an 403 official journal of the International Association for the Study of Obesity. 2011;12(5):e236-e43. 404 Wu T, Gao X, Chen M, Van Dam R. Long-term effectiveness of diet-plus-exercise interventions 6. 405 vs. diet-only interventions for weight loss: a meta-analysis. Obesity reviews. 2009;10(3):313-23. 406 Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and 7. 407 obesity using standard body mass index categories: a systematic review and meta-analysis. Jama. 408 2013;309(1):71-82. 409 8. Loveman E, Frampton G, Shepherd J, Picot J, Cooper K, Bryant J, et al. The clinical effectiveness 410 and cost-effectiveness of long-term weight management schemes for adults: a systematic review. NIHR 411 Health Technology Assessment programme: Executive Summaries. 2011. 412 9. Clifton PM, Bastiaans K, Keogh JB. High protein diets decrease total and abdominal fat and 413 improve CVD risk profile in overweight and obese men and women with elevated triacylglycerol. 414 Nutrition, Metabolism and Cardiovascular Diseases. 2009;19(8):548-54. 415 10. Dorner TE, Rieder A. Obesity paradox in elderly patients with cardiovascular diseases. 416 International journal of cardiology. 2012;155(1):56-65. 417 Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of 11. 418 diabetes, obesity, and other diseases. The lancet Diabetes & endocrinology. 2014;2(10):819-29. 419 12. Garrow JS. Obesity and related diseases: Churchill Livingstone; 1988. 420 13. Prentice AM, Goldberg GR, Jebb SA, Black AE, Murgatroyd PR. Physiological responses to 421 slimming. Proceedings of the Nutrition Society. 1991;50(2):441-58. 422 14. Heymsfield S, Gonzalez M, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth 423 fat-free mass: a critical review and critique of this widely cited rule. Obesity reviews: an official journal 424 of the International Association for the Study of Obesity. 2014;15(4):310-21. 425 15. Heymsfield SB, Ludwig DS, Wong JM, McCarthy C, Heo M, Shepherd J, et al. Are methods of 426 estimating fat-free mass loss with energy-restricted diets accurate? European journal of clinical 427 nutrition. 428 16. Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. Bone. 429 2017;104:101-5. 430 17. Heymsfield SB, Bourgeois B, Ng BK, Sommer MJ, Li X, Shepherd JA. Digital anthropometry: a 431 critical review. European journal of clinical nutrition. 2018;72(5):680. 432 Bennett JP, Liu YE, Quon BK, Kelly NN, Wong MC, Kennedy SF, et al. Assessment of clinical 18. 433 measures of total and regional body composition from a commercial 3-dimensional optical body 434 scanner. Clinical Nutrition. 2022;41(1):211-8. 435 Ng B, Hinton B, Fan B, Kanaya A, Shepherd J. Clinical anthropometrics and body composition 19. 436 from 3D whole-body surface scans. European journal of clinical nutrition. 2016;70(11):1265.

24

437 Wong MC, Ng BK, Kennedy SF, Hwaung P, Liu EY, Kelly NN, et al. Children and Adolescents' 20. 438 Anthropometrics Body Composition from 3-D Optical Surface Scans. Obesity. 2019;27(11):1738-49. 439 Ng BK, Sommer MJ, Wong MC, Pagano I, Nie Y, Fan B, et al. Detailed 3-dimensional body shape 21. 440 features predict body composition, blood metabolites, and functional strength: the Shape Up! studies. 441 The American journal of clinical nutrition. 2019. 442 22. Tian IY, Ng BK, Wong MC, Kennedy S, Hwaung P, Kelly N, et al. Predicting 3D Body Shape and 443 Body Composition from Conventional 2D Photography. Medical Physics. 2020. 444 23. Tian IY WM, Kennedy S, Kelly NN, Yong EL, Garber AK, Heymsfield SB, Curless B, Shepherd JA. A 445 Device-Agnostic Shape Model for Automated Body Composition Estimates from 3D Optical Scans. 446 Medical Physics. 2022. 447 24. Wong MC, Ng BK, Tian I, Sobhiyeh S, Pagano I, Dechenaud M, et al. A pose-independent method 448 for accurate and precise body composition from 3D optical scans. Obesity. 2021;29(11):1835-47. 449 25. Tinsley GM, Harty PS, Stratton MT, Smith RW, Rodriguez C, Siedler MR. Tracking changes in body 450 composition: comparison of methods and influence of pre-assessment standardisation. British Journal of 451 Nutrition. 2021:1-19. 452 Lowe DA, Wu N, Rohdin-Bibby L, Moore AH, Kelly N, Liu YE, et al. Effects of time-restricted 26. 453 eating on weight loss and other metabolic parameters in women and men with overweight and obesity: 454 the TREAT randomized clinical trial. JAMA internal medicine. 2020;180(11):1491-9. 455 27. Macronutrients and body fat accumulation: a mechanistic feeding study 2018. Available from: 456 https://osf.io/m6v73/. 457 28. Jansen LT, Yang N, Wong JM, Mehta T, Allison DB, Ludwig DS, et al. Prolonged Glycemic 458 Adaptation Following Transition From a Low-to High-Carbohydrate Diet: A Randomized Controlled 459 Feeding Trial. Diabetes Care. 2022;45(3):576-84. 460 Wong JM, Yu S, Ma C, Mehta T, Dickinson SL, Allison DB, et al. Stimulated insulin secretion 29. 461 predicts changes in body composition following weight loss in adults with high BMI. The Journal of 462 Nutrition. 2022;152(3):655-62. 463 Scott MC. Exercise and Bone: Older Adults, Type II Diabetes, and Ketogenic Diets: Louisiana 30. 464 State University and Agricultural & Mechanical College; 2021. 465 31. Varanoske AN, Harris MN, Hebert C, Howard EE, Johannsen NM, Heymsfield SB, et al. Effects of 466 testosterone undecanoate on performance during multi-stressor military operations: A trial protocol for the Optimizing Performance for Soldiers II study. Contemporary Clinical Trials Communications. 467 468 2021;23:100819. 469 32. Varanoske AN, Harris MN, Hebert C, Howard EE, Johannsen NM, Heymsfield SB, et al. 470 Testosterone Undecanoate Administration Prevents Declines in Fat-Free Mass but not Physical 471 Performance During Simulated Multi-Stressor Military Operations. Journal of Applied Physiology. 2022. 472 33. Hangartner TN, Warner S, Braillon P, Jankowski L, Shepherd J. The Official Positions of the 473 International Society for Clinical Densitometry: acquisition of dual-energy X-ray absorptiometry body 474 composition and considerations regarding analysis and repeatability of measures. Journal of Clinical 475 Densitometry. 2013;16(4):520-36. 476 Ng BK, Liu YE, Wang W, Kelly TL, Wilson KE, Schoeller DA, et al. Validation of rapid 4-component 34. 477 body composition assessment with the use of dual-energy X-ray absorptiometry and bioelectrical 478 impedance analysis. The American journal of clinical nutrition. 2018;108(4):708-15. 479 35. Loper M, Mahmood N, Romero J, Pons-Moll G, Black MJ. SMPL: A skinned multi-person linear 480 model. ACM transactions on graphics (TOG). 2015;34(6):248. 481 36. Gallagher D, Visser M, De Meersman RE, Sepúlveda D, Baumgartner RN, Pierson RN, et al. 482 Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. Journal of applied physiology. 1997;83(1):229-39. 483

25

- 484 37. Shepherd JA, Lu Y. A generalized least significant change for individuals measured on different 485 DXA systems. Journal of Clinical Densitometry. 2007;10(3):249-58.
- 486 38. Cohen J. A coefficient of agreement for nominal scales. Educational and psychological 487 measurement. 1960;20(1):37-46.
- 488 39. Taylor J. Introduction to error analysis, the study of uncertainties in physical 489 measurements1997.
- 490 40. Maskarinec G, Shvetsov YB, Wong MC, Garber A, Monroe K, Ernst TM, et al. Subcutaneous and 491 visceral fat assessment by DXA and MRI in older adults and children. Obesity. 2022.
- 492 41. Neeland IJ, Grundy SM, Li X, Adams-Huet B, Vega GL. Comparison of visceral fat mass
- 493 measurement by dual-X-ray absorptiometry and magnetic resonance imaging in a multiethnic cohort:
- the Dallas Heart Study. Nutrition & Diabetes. 2016;6(7):e221-e. doi: 10.1038/nutd.2016.28.
- 42. Taylor JL, Holland DJ, Coombes JS, Keating SE. Accuracy of dual-energy x-ray absorptiometry for
 assessing longitudinal change in visceral adipose tissue in patients with coronary artery disease.
 International Journal of Obesity. 2021;45(8):1740-50.
- 498 43. Dias KA, Ramos JS, Wallen MP, Davies PS, Cain PA, Leong GM, et al. Accuracy of longitudinal 499 assessment of visceral adipose tissue by dual-energy X-ray absorptiometry in children with obesity. 500 Journal of Obesity. 2019;2019.
- 501 44. Wu AJ, Rifas-Shiman SL, Taveras EM, Oken E, Hivert MF. Associations of DXA-measured
- abdominal adiposity with cardio-metabolic risk and related markers in early adolescence in Project Viva.
 Pediatric obesity. 2021;16(2):e12704.
- 504 45. Schousboe JT, Langsetmo L, Schwartz AV, Taylor BC, Vo TN, Kats AM, et al. Comparison of
- 505 Associations of DXA and CT Visceral Adipose Tissue Measures With Insulin Resistance, Lipid Levels, and
- 506 Inflammatory Markers. Journal of clinical densitometry: the official journal of the International Society 507 for Clinical Densitometry. 2017;20(2):256-64.
- 50846.Cornell J, Berger R. Factors that influence the value of the coefficient of determination in simple509linear and nonlinear regression models. Phytopathology. 1987;77(1):63-70.

26

Figure Legends

Figure 1. Histograms of the time (weeks) between the baseline and follow-up DXA scans for females (top) and males (bottom). The numbers over the bars represent the count. Multiple numbers over a multi-color bar represent the count in the corresponding order.

Figure 2. Average baseline (left) and follow-up (right) body shapes for females (top) and males (bottom) by study.

Figure 3. (Female) Scatter plot comparisons between 3DO and DXA body composition at baseline, follow-up, and adjusted change. Blue, horizontal lines and orange, vertical lines are signifying the amount of change needed to pass the least significant change for DXA and 3DO, respectively. Purple (Zone 4) and green glyphs (Zone 1) represent agreement of significant or nonsignificant change by 3DO and DXA. The orange glyphs (Zone 3) represent significant change detected by 3DO but not DXA and vice versa for the blue glyphs (Zone 2). The zones and glyphs are consistent for the proceeding adjusted change plots.

Figure 4. (Male) Scatter plot comparisons between 3DO and DXA body composition at baseline, follow-up, and adjusted change. Blue, horizontal lines and orange, vertical lines are signifying the amount of change needed to pass the least significant change for DXA and 3DO, respectively. Purple (Zone 4) and green glyphs (Zone 1) represent agreement of significant or nonsignificant change by 3DO and DXA. The orange glyphs (Zone 3) represent significant change detected by 3DO but not DXA and vice versa for the blue glyphs (Zone 2). The zones and glyphs are consistent for the proceeding adjusted change plots.

Figure 5. Histograms to show the frequency of percent fat-free mass change relative to total weight change in the female (top) and male (bottom) samples.

h	o
Z	o

Study Name (Acronym)	Sex (N)	Intervention	Clinical Trials Number
Athletes	Female 5	Basketball team during training	NA
Bariatric	Female 2	Bariatric surgery	NA
Macronutrients and Body Fat Accumulation: A Mechanistic Feeding Study (FB4: Framingham, Boston, Bloomington, Birmingham, and Baylor)	Female 15; Male 40	Hypocaloric diet with low carbohydrate intake	NCT03394664
Resistance Exercise and Low-Intensity Physical Activity Breaks in Sedentary Time to Improve Muscle and Cardiometabolic Health (REALPA)	Female 8; Male 5	16 weeks of resistance exercise with or without low intensity physical activity breaks in sedentary time or moderate intensity aerobic exercise in older adults	NCT03771417
Time Restricted Eating on Weight Loss (TREAT)	Female 15; Male 27	Time-restricted diet (16 hour fast, 8 hours to feed)	NCT03393195
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations (OPS II)	Male 16	Simulated military operational stress	NCT04120363

Table 1. Descriptions of longitudinal studies.

Complete study protocols can be found on https://clinicaltrials.gov/.

	Female		Male	
	(N=45)		(N=88)	
Age (years)	Baseline	Follow-up	Baseline	Follow-up
Mean (SD)	45.6 (15.7)	45.8 (15.7)	36.3 (13.3)	36.5 (13.3)
Median [Min, Max]	45.9 [18.5, 76.7]	46.2 [18.8, 77.1]	32.0 [19.0, 73.5]	32.0 [19.3, 73.9]
Ethnicity				
Asian	3 (6	.7%)	11 (1	2.4%)
Black	10 (2	2.2%)	7 (7.9%)	
Hispanic	5 (12	1.1%)	7 (7.9%)	
White	27 (6	0.0%)	64 (71.9%)	
Height (cm)				
Mean (SD)	165	(7.46)	177 (6.67)	
Median [Min, Max]	164 [14	49, 185]	176 [1	62, 194]
Weight (kg)				
Mean (SD)	86.7 (17.5)	81.4 (13.2)	97.6 (17.1)	89.4 (17.3)
Median [Min, Max]	82.3 [63.5, 143]	80.6 [63.0, 116]	95.2 [61.5, 142]	87.3 [58.9, 175]
BMI (kg/m ²)				
Mean (SD)	31.8 (6.61)	29.9 (5.00)	31.3 (5.42)	28.7 (5.54)
Median [Min, Max]	30.4 [21.8, 51.3]	29.5 [21.7, 43.7]	30.1 [19.8, 45.8]	27.9 [19.0, 57.3]
DXA Total FM (kg)				
Mean (SD)	34.8 (11.4)	31.3 (8.80)	28.6 (10.8)	23.2 (9.34)
Median [Min, Max]	34.6 [12.9, 68.4]	31.0 [14.0, 54.3]	28.6 [9.14, 67.3]	22.6 [6.00, 53.8]
DXA Total FFM (kg)				
Mean (SD)	52.3 (8.35)	50.5 (7.03)	69.6 (9.24)	66.2 (8.37)
Median [Min, Max]	52.4 [37.5, 77.0]	49.7 [35.9, 67.8]	68.0 [51.4, 91.6]	65.4 [49.6, 90.9]
DXA Percent Fat (%)				
Mean (SD)	39.3 (7.21)	37.8 (6.66)	28.3 (6.96)	25.2 (7.07)
Median [Min, Max]	41.8 [19.9, 51.5]	40.2 [20.6, 46.9]	29.1 [11.1, 47.4]	25.9 [7.81, 43.9]
DXA ALM (kg)				
Mean (SD)	11.3 (2.17)	11.0 (1.87)	15.8 (2.23)	15.1 (2.04)
Median [Min, Max]	11.6 [7.31, 15.6]	10.7 [7.52, 15.0]	15.8 [11.2, 20.9]	14.8 [10.8, 20.9]
DXA VAT (kg)				
Mean (SD)	0.56 (0.27)	0.53 (0.26)	0.56 (0.28)	0.46 (0.23)
Median [Min, Max]	0.51 [0.13, 1.10]	0.52 [0.12, 1.29]	0.50 [0.16, 1.40]	0.40 [0.13, 1.15]
DXA Arm FM (kg)				
Mean (SD)	2.14 (0.83)	1.92 (0.60)	1.78 (0.84)	1.46 (0.67)
Median [Min, Max]	2.04 [0.73, 5.32]	1.94 [0.79, 3.53]	1.61 [0.52, 4.94]	1.39 [0.36, 3.82]
DXA Arm FFM (kg)				
Mean (SD)	2.68 (0.51)	2.59 (0.44)	4.34 (0.73)	4.13 (0.66)
Median [Min, Max]	2.62 [1.79, 4.01]	2.49 [1.80, 3.74]	4.30 [2.93, 6.42]	4.10 [2.78, 6.19]
DXA Leg FM (kg)				
Mean (SD)	6.54 (2.18)	5.97 (1.75)	4.67 (1.70)	3.86 (1.42)

Table 2. Sample characteristics at baseline and follow-up visits

30

ſ	Median [Min, Max]	6.02 [2.90, 13.1]	5.89 [3.13, 10.8]	4.45 [1.65, 10.9]	3.88 [1.08, 9.16]
DXA Leg FFM (kg)					
ſ	Mean (SD)	8.64 (1.72)	8.37 (1.48)	11.4 (1.61)	11.0 (1.48)
ſ	Median [Min, Max]	8.75 [5.52, 12.0]	8.24 [5.72, 11.3]	11.3 [7.94, 15.1]	10.8 [7.62, 15.1]
DXA Trunk FM (kg)					
ſ	Mean (SD)	16.3 (6.16)	14.4 (4.79)	14.4 (6.10)	11.3 (5.48)
ſ	Median [Min, Max]	16.6 [4.61, 34.9]	14.8 [4.73, 24.5]	14.1 [3.52, 34.3]	10.8 [2.16, 26.6]
DXA Trunk FFM (kg)					
ſ	Mean (SD)	26.1 (4.31)	25.0 (3.81)	33.9 (4.88)	31.9 (4.44)
ſ	Median [Min, Max]	25.7 [19.2, 41.6]	23.9 [17.5, 37.4]	33.5 [25.1, 46.4]	31.7 [23.8, 44.3]

Abbreviations: FM (fat mass); FFM (fat-free mass); ALM (appendicular lean mass); DXA (dual-energy X-ray absorptiometry); VAT (visceral adipose tissue)















